On April 26, the inauguration of Guangdong Hong Kong Macao Dawan District innovative vaccine technology industrial transformation center jointly organized by Guangdong Provincial Laboratory of regenerative medicine and health (hereinafter referred to as “Biological Island laboratory”) and Yipinhong Pharmaceutical Co.Ltd(300723) ( Yipinhong Pharmaceutical Co.Ltd(300723) ) was held in Guangzhou International Biological Island.
After the outbreak of covid-19, the vaccine industry has become the key field of a new round of global biomedicine and health industry, and it is also the main direction of China’s strategic industrial layout. Guangzhou International Biological Island, as a scientific and technological frontier for the innovation and development of biomedicine in the Dawan District of Guangdong, Hong Kong and Macao, in order to accelerate the establishment of a global leading vaccine Incubation Platform and quickly realize the breakthrough of key vaccine technologies, the “Guangdong, Hong Kong and Macao Dawan District innovative vaccine technology industrial transformation center” with the joint construction of advantageous scientific research institutions and excellent innovative pharmaceutical enterprises in the Dawan district and the industrialization of innovative vaccines as the focus came into being.
The transformation center is jointly built by bio Island laboratory and Yipinhong Pharmaceutical Co.Ltd(300723) Co., Ltd. through the investment of funds and resources from both sides, strong alliances, complementary advantages and the integrated development of industry, University and research, it will help more scientists and innovative vaccine technology enterprises to research, develop and transform, and promote the industrialization and large-scale application. The specific work contents include accelerating the realization of large-scale production technology and providing demonstration application platform, building a new cdmo platform with the functions of cooperative development, achievement transformation and investment incubation, building and integrating the existing pilot platform and production resources, and promoting the international innovative development and industrial transformation process of recombinant protein vaccine, nucleic acid vaccine and virus vector vaccine in Guangdong, Hong Kong and Macao, Promote the upstream and downstream development of vaccine industry in Dawan district.
It is reported that the Biological Island laboratory, established in 2017, is one of the first batch of provincial laboratories launched in Guangdong Province. The director of the laboratory is Xu Tao, academician of the Chinese Academy of Sciences. Many young scientific research backbones have been selected into the national and local talent plan. By the end of 2021, 48 national, provincial and municipal scientific research projects have been approved. It has the ability to tackle key scientific and technological tasks and build major scientific and technological infrastructure.
Statistics show that Yipinhong Pharmaceutical Co.Ltd(300723) is a pharmaceutical innovation enterprise dedicated to drug innovation and high-end drug R & D, integrating R & D, production and sales. At present, there are 261 R & D teams led by senior scientists around the world, with more than 50 projects under research. In 2021, independent R & D and value-added R & D invested 660 million yuan, and 13 newly approved products, ranking among the top 15 Chinese enterprises.
As early as 2011, Yipinhong Pharmaceutical Co.Ltd(300723) laid out the field of biological gene vaccine in advance, and built platforms such as national enterprise technology center and national enterprise postdoctoral research workstation. Many projects have been listed in the national major new drug creation projects of the 13th five year plan. They have rich experience in drug R & D and achievement transformation, as well as mature industrialization system, which can provide solid support for the achievement transformation of the transformation center.
Academician Xu Tao of Biological Island laboratory will serve as the first chairman of the transformation center to guide the work of the transformation center. Next, the transformation center will focus on the needs of biological vaccine industry in Dawan District, improve the construction of vaccine analysis and test platform and pilot test platform, select excellent vaccine projects at home and abroad, and provide achievement transformation and market-oriented services for their landing in Dawan district.
It is understood that the transformation center will be South China vaccine, a subsidiary of Yipinhong Pharmaceutical Co.Ltd(300723) holding company, which is mainly responsible for the construction of technology platform and the transformation of vaccine industry Yipinhong Pharmaceutical Co.Ltd(300723) focuses on the innovative research and development of recombinant protein nanoparticle vaccine. It has completely independent intellectual property rights of insect cell baculovirus expression system, mature production and protein purification process, adjuvant research and development and production and other technologies. At present, more than 5000 square meters of recombinant protein R & D and pilot plant have been built, with multiple vaccine product pipelines such as recombinant protein vaccine and influenza virus recombinant protein vaccine.
